$1.25
-0.085-6.39%
Last update: Nov 2, 1:16 PM
RenovoRx Inc (RNXT) Stock Price, Quote, News & History
RNXTNASDAQ
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
You can purchase shares of RenovoRx (NASDAQ:RNXT) through any online brokerage.
Other companies in RenovoRx’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
RenovoRx has a consensus price target of $7.17.
The stock price for RenovoRx (NASDAQ: RNXT) is $1.245 last updated November 2, 2026 at 1:16 PM EST.
There are no upcoming dividends for RenovoRx.
RenovoRx does not have any upcoming earnings scheduled.
There is no upcoming split for RenovoRx.
RenovoRx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented...
